Exendin-(9-39) for Post-Bariatric Surgery Glucose Metabolism
(GLP-1 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism.The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims.1. To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp.2. To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals.3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is exendin-(9-39) safe for humans?
Exendin-(9-39) has been studied for its effects on glucose metabolism and is generally considered safe, with no significant adverse effects reported in the studies reviewed. It does not activate the GLP1 receptor, which may result in fewer side effects compared to similar compounds like exendin-4.12345
How does the drug Exendin-(9-39) differ from other treatments for post-bariatric surgery glucose metabolism?
Exendin-(9-39) is unique because it acts as an antagonist to glucagon-like peptide 1 (GLP-1), which means it blocks the effects of GLP-1, a hormone involved in insulin release and glucose regulation. This is different from other treatments that typically enhance GLP-1 activity to lower blood sugar levels.12678
What data supports the effectiveness of the drug exendin-(9-39) for post-bariatric surgery glucose metabolism?
Research shows that exendin-(9-39) can block the effects of GLP-1, a hormone that lowers blood sugar, which suggests it might help manage blood sugar levels in people with post-bariatric hypoglycemia. Additionally, studies have evaluated its safety and effectiveness in patients with this condition, indicating potential benefits.12567
Who Is on the Research Team?
Marzieh Salehi, MD,MS
Principal Investigator
Marzieh Salehi
Are You a Good Fit for This Trial?
This trial is for adults aged 18-65 who have had gastric bypass surgery and are experiencing recurrent low blood sugar. Healthy individuals without diabetes or active organ disease can also participate. People with significant anemia, current diabetes (unless awaiting bariatric surgery), pregnancy, or GI obstruction cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo hyperglycemic clamp and meal tolerance tests to evaluate the effect of incretin hormones and GLP-1 receptor blockade on glucose metabolism
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- exendin -(9-39)
- exendin-(9-39)
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas Health Science Center at San Antonio
Lead Sponsor